International Journal of STD & AIDS > Volume 12, Number 5 > Pp. 286-294

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Youle, M. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Continuing professional development

Salvage treatment in HIV disease

Mike Youle

Director HIV Clinical Research, Royal Free Centre for HIV Medicine, Garrett Anderson Ward, Royal Free Hospital, Pond Street, London NW3 2QG, UK

The need for salvage treatment is related to the imperfection of current antiretroviral therapy. Sequential therapy with suboptimally suppressive regimens results in a need for this intervention. The aim of salvage treatment is as yet uncertain; virological suppression; immunoenhancement or stability or avoidance of clinical disease. Therapeutic options are constantly improving and the knowledge base concerning individual agents and different combinations comprising highly active antiretroviral treatment (HAART) regimens increases daily. The utility of new agents in salvage appears vital with numbers of new or recycled agents to which no demonstrable resistance exists is a major predictive factor of a positive outcome in this setting. Patient commitment, physician knowledge and an informed supportive environment are also conducive to success in salvage treatment.

Key Words: SALVAGE • MEGA-HAART • HIV TREATMENT

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E J Beck, S Mandalia, M Youle, R Brettle, M Fisher, M Gompels, G Kinghorn, B McCarron, A Pozniak, A Tang, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002) Int J STD AIDS, May 1, 2008; 19(5): 297 - 304. [Abstract] [Full Text] [PDF]